Navigation Links
'Ecstasy' May Cause Long-Term Changes in Brain Chemistry
Date:12/13/2011

By Alan Mozes
HealthDay Reporter

TUESDAY, Dec. 13 (HealthDay News) -- Recreational use of the illegal drug known as ecstasy is associated with long-term changes in brain chemistry, a small, new study reveals.

Based on research with women, it appears that the so-called "rave" drug can induce a drop in serotonin levels that can last up to two years. Serotonin, the research team noted, is critical to the regulation of mood, appetite, sleep, learning and memory.

"We've always known that ecstasy produced transient effects, but with the suggestion that there would be recovery over time," explained study co-author Dr. Ronald Cowan, an associate professor of psychiatry in the department of psychiatry with Vanderbilt University Medical Center's School of Medicine in Nashville, Tenn. "But here we find that these effects may be sustained over time with no evidence of reversal," he added.

"Now this is an observational study, so we can't do really any more than suggest causation," Cowan noted. "But I would say that this is nevertheless the strongest evidence we have that there is chronic change in serotonin levels for those who use the drug."

Cowan and his colleagues report their findings in the Dec. 5 online issue of the Archives of General Psychiatry.

The authors noted that nearly 16 million Americans aged 12 and older have reportedly used ecstasy at some point in their life.

As described by the U.S. National Institute on Drug Abuse, ecstasy (otherwise known by its chemical name, MDMA) is a psychoactive stimulant that is similar in structure to methamphetamine and mescaline.

The drug increases serotonin levels in the brain, and users feel a sense of euphoria and emotional warmth. On the downside, the institute notes that the drug prompts a potentially problematic increase in both heart rate and blood pressure, and can lead to sleep disturbance and lingering feelings of confusion, depression and anxiety.

On the other end of the spectrum, some researchers have pointed to the therapeutic potential for the controlled, clinical use of MDMA to help patients struggling with post-traumatic stress disorder (PTSD) and/or dysfunctional social skills.

Cowan's team focused on 24 women, including 14 who were described as MDMA users. The study was confined to women to avoid the complication of gender-specific serotonin level differences between men and women.

The average age of the women was 22. Cowan noted that those who were MDMA users had taken ecstasy for a period of between three to four years, with the number of pills taken ranging from just five to roughly 375 overall. At the start of the study, all had abstained from ecstasy use for a minimum of 90 days, with the average length of abstinence hovering at the two-year mark.

The team used positron emission tomography (PET) scans to assess levels of serotonin receptors in the participants' brains, noting that receptor levels are known to go up as serotonin levels go down. Those women who had a history of taking ecstasy had higher receptor levels than women who hadn't, suggesting a drop in serotonin levels among MDMA users.

What's more, the team observed a dose-dependent impact: The more ecstasy a woman had taken in her lifetime, the higher her receptor levels.

"We don't actually know what the implications are," acknowledged Cowan. "There is some evidence in prior research that a drop in serotonin leads to sleep apnea, depression, anxiety and memory loss. But in our work we didn't find evidence of mental health issues. No increased anxiety, impulsivity or depression. And the IQs of the women who took the drug were identical with those who had never taken it," he stated.

"We also have no proof that a drop in serotonin levels would be forever," Cowan noted. "Animal studies have indicated that there could be as much as a seven-year duration in such dips. But we don't know. So, this work raises serious concerns and questions, but more research is needed."

Michael Mithoefer, a clinical researcher in the field of MDMA-assisted psychotherapy for PTSD, stressed "the importance of not jumping to conclusions."

"You have to be careful with research like this," Mithoefer cautioned. "There have been some other similar studies suggesting the possibility of some long-term changes with ecstasy use. But the problem with retrospective studies based on self-report is that there are other factors at play that might not be accounted for. Did these people take other drugs at the same time? Was it really MDMA that they took? Exactly how much did they take? What really was the dose taken? That kind of thing can become very unclear when you're asking people to remember past behavior," he explained.

"It's also the case that in clinical research conducted with a few different doses of pure MDMA we have no found evidence of these kinds of problems," noted Mithoefer.

"I do, however, think it's important that people not think that MDMA is without risk," he added. "Especially with recreational use in an uncontrolled setting. Whether that will lead to mental health issues or not is unclear. But it is certainly something that bears further study."

More information

For more on ecstasy, visit the U.S. National Institute on Drug Abuse.

SOURCES: Ronald L. Cowan, M.D., Ph.D., associate professor, psychiatry, department of psychiatry, school of medicine, Vanderbilt University Medical Center, Nashville, Tenn.; Michael Mithoefer, M.D., psychiatrist, private practice, Charleston, S.C.; Dec. 5, 2011, Archives of General Psychiatry, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Ecstasy Use May Make Brain Less Efficient
2. Ecstasy associated with chronic change in brain function
3. Long-Term Ecstasy Users at Risk for Brain Damage, Study Warns
4. New study finds no cognitive impairment among ecstasy users
5. Does Club Drug Ecstasy Have Therapeutic Value?
6. Use of Marijuana, Ecstasy, Methamphetamine on Rise in U.S.
7. Researchers Use Ecstasy to Treat PTSD
8. Major cause of chronic kidney disease-related inflammation is identified
9. Side Effects Cause Many Older Women to Drop Breast Cancer Drugs
10. The disappearance of the elephant caused the rise of modern man
11. B cell receptor inhibitor causes chronic lymphocytic leukemia remission
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Ecstasy' May Cause Long-Term Changes in Brain Chemistry 
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology: